TVAX Biomedical, Inc.

TVAX Biomedical is a clinical stage development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved clinical outcomes and low toxicity and the potential for fundamentally changing the way cancer is treated. Current treatment options for cancer, which include surgery, radiation and/or chemotherapy, are not adequately meeting patient treatment needs. Radiation and chemotherapy in particular are highly toxic and rarely “cure” the patient by permanently eliminating the cancer. With more than 1.5 million new cases of cancer diagnosed and more than 500,000 cancer deaths in the U.S. each year, more effective, less toxic treatment options are desperately needed.